BioCorRx Inc. (BICX)
OTCMKTS
· Delayed Price · Currency is USD
0.3400
0.00 (0.00%)
Jun 11, 2025, 10:18 AM EDT
BioCorRx Revenue
BioCorRx had revenue of $134.90K in the quarter ending March 31, 2025, with 3,626.49% growth. This brings the company's revenue in the last twelve months to $138.94K, up 165.47% year-over-year. In the year 2024, BioCorRx had annual revenue of $7.67K, down -91.40%.
Revenue (ttm)
138.94K
Revenue Growth
+165.47%
P/S Ratio
44.04
Revenue / Employee
46.31K
Employees
3
Market Cap
6.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.67K | -81.50K | -91.40% |
Dec 31, 2023 | 89.16K | -124.68K | -58.31% |
Dec 31, 2022 | 213.84K | 165.57K | 342.99% |
Dec 31, 2021 | 48.27K | -74.35K | -60.63% |
Dec 31, 2020 | 122.62K | -117.64K | -48.96% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
BioCorRx News
- 10 months ago - BioCorRx GAAP EPS of -$0.13, revenue of $4.04M - Seeking Alpha
- 10 months ago - BioCorRx Reports Business Update for the Second Quarter of 2024 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for 2023 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors - GlobeNewsWire
- 1 year ago - BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for the Third Quarter of 2023 - GlobeNewsWire